An LPA genetic test examines inherited variation in the LPA gene, which strongly influences blood levels of lipoprotein(a), usually written as Lp(a). High Lp(a) is a causal risk factor for atherosclerotic cardiovascular disease and calcific aortic valve stenosis, but DNA testing is not usually the first or most useful way to assess that risk. A direct Lp(a) blood measurement is simpler, captures the combined effect of many LPA variants, and is the result most clinical guidelines use. Genetic testing may still help in research, selected family investigations, or situations where a laboratory is evaluating specific variants or the complex kringle IV type 2 copy-number region. The result must be interpreted alongside the actual Lp(a) concentration, LDL cholesterol, blood pressure, diabetes, smoking, kidney disease, family history, and any existing heart or vascular disease. It does not diagnose a current blockage or predict the exact age of a heart attack.
- The clinically preferred test is usually a blood Lp(a) level, not an LPA DNA test.
- Lp(a) is highly heritable and often stays relatively stable throughout adult life, so one measurement is enough for many people.
- Values at or above about 50 mg/dL or 125 nmol/L are commonly treated as elevated, but units are not directly interchangeable.
- A high-risk LPA variant can support inherited susceptibility, yet it cannot substitute for measuring the particle concentration.
- Lifestyle changes improve overall cardiovascular risk but usually have little effect on the genetically determined Lp(a) level itself.
- First-degree relatives of someone with markedly elevated Lp(a) should discuss direct blood testing, even if they feel healthy.
Table of Contents
- What LPA and Lp(a) Mean
- Blood Testing Versus Genetic Testing
- The Genetic Features of LPA
- Who May Be Tested
- Interpreting LPA Genetic Results
- Understanding Lp(a) Blood Levels and Units
- Reducing Heart and Aortic Valve Risk
- Family Testing, Limitations, and Follow-Up
What LPA and Lp(a) Mean
LPA is the gene that contains instructions for making apolipoprotein(a). Lipoprotein(a), abbreviated Lp(a), is a blood particle formed when apolipoprotein(a) attaches to an LDL-like particle containing apolipoprotein B100. The similar lettering causes confusion: LPA is the gene; Lp(a) is the circulating lipoprotein that a laboratory measures in blood.
Lp(a) can promote cardiovascular disease through several pathways. Its LDL-like core carries cholesterol into artery walls. Apolipoprotein(a) also carries oxidized phospholipids that can promote inflammation and calcification. High concentrations are associated with coronary heart disease, ischemic stroke, peripheral artery disease, and calcific aortic valve stenosis.
The risk is continuous rather than divided into a perfect normal-abnormal boundary. In general, higher lifelong exposure brings greater risk. A person with 180 nmol/L usually has more Lp(a)-related risk than someone with 40 nmol/L, but the total clinical meaning depends on the rest of the cardiovascular profile. High Lp(a) is especially important when it accompanies high LDL cholesterol, smoking, hypertension, diabetes, or a strong family history of early heart disease.
Lp(a) is different from the APOB-related causes of high LDL cholesterol and from classic familial hypercholesterolemia. A person can have elevated Lp(a) with an otherwise ordinary LDL-C result. Conversely, someone can have both high Lp(a) and an LDLR, APOB, or PCSK9 variant, creating a larger cumulative burden.
Standard lipid panels do not always include Lp(a). The LDL-C calculation can also include cholesterol carried within Lp(a), so part of an apparently resistant LDL-C value may reflect Lp(a)-cholesterol rather than ordinary LDL particles. This does not make the LDL result meaningless, but it can affect specialist interpretation.
Blood Testing Versus Genetic Testing
For routine care, direct Lp(a) measurement is usually more informative than LPA genotyping. The blood test captures the net effect of kringle repeat number, single-nucleotide variants, ancestry-related allele patterns, and other regulatory influences. It also produces the value used in clinical risk discussions.
An LPA genetic test may report one or more of the following:
- Common variants associated with higher Lp(a), such as rs10455872 or rs3798220.
- Estimated kringle IV type 2, or KIV-2, copy number.
- Apo(a) isoform size inferred from DNA.
- Rare sequence variants that raise, lower, or disrupt apolipoprotein(a) production.
- A polygenic estimate of genetically predicted Lp(a) concentration.
No single common variant explains all high Lp(a). A person may lack rs10455872 and rs3798220 yet still have a very high concentration because of other LPA features. These variants also have different frequencies and predictive value across ancestry groups. A “negative” common-variant test therefore cannot rule out inherited elevation.
KIV-2 testing is technically challenging. The LPA gene contains a repeated region in which the kringle IV type 2 unit can occur a few times or dozens of times. In general, fewer repeats are associated with smaller apo(a) isoforms and higher Lp(a), but the relationship is not exact for every allele. Standard short-read sequencing may not fully resolve the repeat structure or assign copies to the maternal and paternal alleles.
A direct blood test avoids many of these interpretive problems. It is generally inexpensive, requires no fasting in most settings, and can be ordered with a lipid panel. The 2022 European and 2024 U.S. expert statements support broad adult measurement, often at least once in a lifetime.
Genetic analysis may still add value when researchers are studying causal pathways, when a family has discordant laboratory results, or when specialized laboratories need allele-specific information. It can also appear as part of broad genome sequencing. In those situations, the DNA result should usually prompt a measured Lp(a) level rather than replace it.
The Genetic Features of LPA
LPA variation explains most of the person-to-person difference in Lp(a). Estimates vary by population and method, but roughly 70% to 90% of the concentration is often considered genetically determined. Levels therefore tend to cluster in families and remain much more stable than triglycerides or LDL-C.
Each person usually carries two LPA alleles, one from each parent. The alleles can produce apo(a) proteins of different sizes and at different rates. The measured blood concentration reflects their combined output. This inheritance is sometimes described as codominant because both alleles contribute.
The major structural feature is KIV-2 copy-number variation. Apolipoprotein(a) contains multiple kringle-shaped domains. A variable number of KIV-2 repeats changes protein size. Smaller isoforms are often secreted more efficiently and are commonly associated with higher concentrations. Larger isoforms are often associated with lower concentrations, though sequence variation within or outside the repeats can modify that pattern.
Several common single-nucleotide variants are useful in population studies. The rs10455872 variant is associated with fewer KIV-2 repeats and higher Lp(a) in many people of European ancestry. The rs3798220 variant can also be associated with high levels and cardiovascular risk. Their frequency and predictive performance differ substantially across populations, so a two-variant test has limited universal clinical value.
Some LPA variants lower Lp(a) or produce a null allele that makes little or no apo(a). Others affect RNA splicing, protein assembly, or secretion. Emerging long-read sequencing methods can characterize this complex locus more accurately, but such analysis is not yet routine in most cardiovascular clinics.
Ancestry affects the distribution of Lp(a) concentrations and isoforms. On average, people of African ancestry often have higher measured levels than people of European or East Asian ancestry, but there is wide overlap and individual testing is still necessary. Risk cannot be inferred reliably from race or ethnicity, and a universal decision should not be based on ancestry alone.
Unlike a single-gene disorder with a simple positive or negative diagnosis, LPA variation usually changes a quantitative trait. The result is better understood as a contributor to a measured biomarker than as proof of a discrete disease.
Who May Be Tested
Most adults can reasonably have Lp(a) measured at least once. Direct measurement is particularly important when the result could explain unexpectedly high cardiovascular risk or change the intensity of prevention.
Clinical situations that support measurement include:
- Premature coronary artery disease, ischemic stroke, or peripheral artery disease.
- A first-degree relative with early heart attack, stroke, or markedly elevated Lp(a).
- Familial hypercholesterolemia or very high untreated LDL-C.
- Recurrent cardiovascular events despite well-controlled LDL-C.
- Calcific aortic valve stenosis, especially at a younger age.
- Borderline estimated risk where an additional risk enhancer could change treatment.
- Children in a family with markedly elevated Lp(a), premature disease, or familial hypercholesterolemia.
An LPA genetic test may be considered when it is part of a research protocol, a specialized lipid evaluation, or broad genomic analysis. It may also be used when a clinician wants to investigate why measured values differ sharply among close relatives or why an assay result appears inconsistent with apo(a) isoform information.
Genetic testing is usually not needed merely because Lp(a) is above 50 mg/dL or 125 nmol/L. The high concentration itself already demonstrates the clinically relevant exposure. Ordering DNA testing after that result may add cost without changing management.
Likewise, a coronary artery disease polygenic risk score is not a substitute for Lp(a) measurement. A CAD score combines many common variants across the genome, while Lp(a) is a specific, largely LPA-driven biomarker with its own causal pathway. The two can provide complementary information but answer different questions.
Children do not need repeated frequent testing unless a clinician identifies a reason. Levels are genetically determined but can change during growth, and some experts prefer measurement after early childhood or repeat confirmation if the initial value is unexpected. Decisions should consider the family history and whether the result will lead to practical prevention.
Interpreting LPA Genetic Results
LPA reports vary widely because there is no single standardized “positive” result used across all laboratories. Some reports list a risk allele, some estimate KIV-2 copy number, and others provide a predicted concentration or percentile.
| Finding | What it may suggest | What it cannot establish |
|---|---|---|
| High-Lp(a)-associated common variant | Greater inherited probability of an elevated concentration | The actual Lp(a) level or an individual event date |
| Low estimated KIV-2 copy number | Tendency toward smaller apo(a) isoforms and higher Lp(a) | A precise concentration in every ancestry or allele combination |
| No tested risk variant | The selected markers were absent | Normal Lp(a), because many other LPA variants exist |
| Rare loss-of-function variant | Potentially reduced apo(a) production from one allele | Complete protection from cardiovascular disease |
| Genetically predicted high Lp(a) | Elevated inherited exposure is likely | Confirmation without a standardized blood measurement |
A report may use odds ratios or percentile ranks. These are population-level measures, not personal probabilities. An odds ratio of 1.5 for a variant does not mean the person has a 50% chance of a heart attack. Absolute risk depends on baseline age, sex, blood pressure, LDL-C, smoking, diabetes, existing disease, and treatment.
Variants of uncertain significance are particularly difficult at LPA because the gene is repetitive and highly variable. A rare change may alter protein production, have no effect, or be difficult to phase with the KIV-2 allele. A VUS should not be used to label relatives as high risk when a blood Lp(a) measurement can answer the more direct clinical question.
When the genetic prediction and blood level disagree, the measured concentration usually guides current care. The team should confirm units, assay method, sample identity, acute medical conditions, kidney function, and whether the genetic model was validated for the person’s ancestry.
Understanding Lp(a) Blood Levels and Units
Lp(a) is reported in either milligrams per deciliter (mg/dL), which measures mass, or nanomoles per liter (nmol/L), which better reflects particle concentration. Because apo(a) isoform size varies, there is no exact universal conversion between the units. Multiplying by a fixed factor can be misleading.
Many clinical frameworks use approximate categories such as:
| Category | Mass concentration | Molar concentration |
|---|---|---|
| Lower risk range | Below 30 mg/dL | Below 75 nmol/L |
| Intermediate or gray zone | 30 to 49 mg/dL | 75 to 124 nmol/L |
| Risk-enhancing level | 50 mg/dL or higher | 125 nmol/L or higher |
These cutoffs help communication but should not imply that 49 mg/dL is safe and 50 mg/dL is suddenly dangerous. Risk rises across the distribution. Very high values, such as above 180 mg/dL or roughly 430 nmol/L, may confer a lifetime risk burden comparable to heterozygous familial hypercholesterolemia in some analyses.
Fasting is usually unnecessary. Lp(a) is relatively stable, but levels can shift with major inflammation, pregnancy, menopause, kidney disease, liver disease, or acute illness. Repeat testing may be reasonable when the value is near a treatment threshold, unexpectedly extreme, obtained during serious illness, or measured with a questionable assay.
Assays should ideally be minimally affected by apo(a) isoform size and traceable to accepted standards. Comparing values from different laboratories requires attention to units and method. A result in mg/dL should not be converted to nmol/L with a simple online multiplier and treated as exact.
Reducing Heart and Aortic Valve Risk
There is no widely available lifestyle method that reliably lowers the genetically determined Lp(a) concentration by a large amount. That does not make lifestyle unimportant. Stopping smoking, maintaining healthy blood pressure, exercising appropriately, treating diabetes, sleeping adequately, and following a heart-healthy dietary pattern reduce other pathways that combine with Lp(a) to cause events.
The main current strategy is aggressive control of modifiable risk, especially LDL-C and apoB-containing particles. Statins do not lower Lp(a) and may cause a small increase in some people, but they reduce cardiovascular events by lowering LDL-driven risk and remain important when indicated. A high Lp(a) result is not a reason to avoid statins.
Ezetimibe has little consistent effect on Lp(a) but can lower LDL-C. PCSK9 inhibitors lower LDL-C substantially and often reduce Lp(a) by roughly 20% to 30%. Their use is based on the person’s overall cardiovascular indication, not solely on an LPA genotype. The PCSK9 genetic test addresses a separate inherited cholesterol pathway.
Lipoprotein apheresis can lower Lp(a) temporarily and is used in selected people with progressive cardiovascular disease under country-specific criteria. It requires repeated treatments because levels rebound.
Several antisense and small-interfering RNA therapies are designed to reduce apo(a) production and can lower Lp(a) dramatically in trials. The decisive question is whether lowering Lp(a) reduces heart attacks, strokes, and other clinical events. Availability and regulatory approval can change, so treatment decisions should rely on current specialist guidance rather than promotional claims.
Aspirin is not automatically recommended for everyone with high Lp(a). Bleeding risk, age, existing cardiovascular disease, and overall prevention strategy matter. The same is true for coronary calcium scanning and other imaging: they may refine risk in selected adults but are not required by the genetic result alone.
Family Testing, Limitations, and Follow-Up
Because Lp(a) is highly heritable, first-degree relatives of someone with a markedly elevated level should discuss direct measurement. Cascade blood testing often provides more useful information than testing relatives for one common LPA variant.
A family can show wide variation. One child may inherit the high-producing allele, another may inherit a lower-producing allele, and both may have different LDL-C, blood pressure, and lifestyle exposures. Each relative needs an individual result rather than an assumption based on the family average.
A negative limited LPA genotype does not provide reassurance if the concentration has never been measured. Common commercial tests may examine only a small number of variants and may perform differently across ancestry groups. Consumer raw-data interpretations are especially limited because they usually cannot resolve KIV-2 copy number or the full repetitive locus.
After a high Lp(a) result, useful next steps include:
- Confirming the units and assay method.
- Reviewing LDL-C, non-HDL cholesterol, apoB, blood pressure, glucose status, and smoking.
- Documenting premature cardiovascular disease and aortic stenosis in the family.
- Considering earlier or more intensive prevention based on absolute risk.
- Offering one-time Lp(a) measurement to close relatives.
- Reassessing treatment as outcome-trial evidence and approved therapies evolve.
An LPA genetic result can explain biology, but the blood concentration and the person’s overall cardiovascular profile determine clinical action. The safest interpretation avoids two errors: dismissing a high Lp(a) because common risk variants were absent, and treating a risk allele as though it were a diagnosis of current artery disease.
People should also distinguish Lp(a) from lifestyle-responsive cholesterol markers when discussing results with family members. A relative may assume that a healthy diet guarantees a low value, while another may feel that an inherited high value makes prevention pointless. Both conclusions are incorrect. Diet and activity may not substantially change Lp(a), yet they can lower blood pressure, improve glucose control, reduce triglycerides, support healthy weight, and decrease the total burden placed on arteries.
Repeat measurement is not routinely needed every year, but it can be appropriate after a major change in health. Chronic kidney disease, nephrotic syndrome, severe inflammation, pregnancy, and some hormonal transitions can alter measured concentrations. A laboratory switch can also create an apparent change when one assay reports mass and another reports particle concentration. Clinicians should compare like with like before deciding that the biology has changed.
The report should remain in the medical record even when no immediate medication change follows. Lp(a) can influence future choices about LDL-C targets, preventive intensity, referral to a lipid specialist, and eligibility for clinical trials or newly approved therapies. Because the treatment landscape is evolving, a result obtained once can become more actionable later without requiring repeated genetic testing.
References
- A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice 2024 (Position Statement)
- Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement 2022 (Position Statement)
- Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement From the American Heart Association 2022 (Position Statement)
- Why, how and in whom should we measure levels of lipoprotein(a): Insights from current guidelines 2025 (Review)
- Lipoprotein(a) 2023 (Review)
- Identification of allele-specific KIV-2 repeats and impact on Lp(a) measurements and genetic epidemiology 2024 (Review)
Disclaimer
This article provides general information about LPA genetics and Lp(a) testing and does not replace individual cardiovascular assessment. Treatment should be based on a standardized Lp(a) measurement, overall risk, medical history, and current professional guidance. Do not start or stop cholesterol, antiplatelet, or other cardiovascular medication based on a consumer genetic result alone.
